RxDoctor Payments Data

Lawrence McDermott

Pulmonary Disease · Savannah, GANPI 1801838818

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $958,265 of the $962,533 with a category attached, or 99.6%. Teva Pharmaceuticals USA, Inc. accounts for 60.5% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $644,320 and has fallen 100.0% since, to $62 in 2025. Among pulmonary disease clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$962,533in general payments, 2019–2025

Across 53 payments — averaging $18,161 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$582K
  • AstraZeneca$233K
  • Incyte Corporation$147K
  • Madrigal Pharmaceuticals$62

What the payments were for

  • Consulting fees$958,265100%
  • Travel & lodging$4,2060%
  • Education$620%

General payments by program year

19
20
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$962,533 in reported general payments places this provider in the 95th percentile of 365 pulmonary disease providers in Georgia.

See all pulmonary disease providers in Georgia

Other pulmonary disease in Savannah

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →